Characteristics of the entire cohort
| Patient characteristics . | Entire cohort (N = 49) . | PV (n = 24) . | ET (n = 25) . |
|---|---|---|---|
| Sex, male/female | 30/19 | 18/6 | 12/13 |
| Age at diagnosis (range), y | 63 (26-82) | 65 (42-81) | 59 (26-82) |
| Hemoglobin at diagnosis (range), g/dL | 16 (10-20.7) | 18.1 (16-20.7) | 14.4 (10-16.6) |
| Platelets at diagnosis (range), ×109/L | 624 (139-1575) | 404 (139-748) | 800 (471-1575) |
| Leukocytes at diagnosis (range), ×109/L | 9.17 (3-27.8) | 10.6 (5.1-27.8) | 8.4 (3-17.3) |
| Driver mutation, n (%) | |||
| JAK2V617F | 39 (80) | 24 (100) | 15 (60) |
| CALR | 6 (12) | — | 6 (24) |
| MPL | 2 (4) | — | 2 (8) |
| Triple negative | 2 (4) | — | 2 (8) |
| Treatment of chronic phase | |||
| Treatments, n (range) | 1 (1-5) | 1 (1-4) | 1 (1-5) |
| Hydroxycarbamide, n (%) | 39 (80) | 20 (83) | 19 (76) |
| Pipobroman, n (%) | 17 (35) | 10 (42) | 7 (28) |
| Peg IFN-α, n (%) | 6 (12) | 2 (8) | 4 (16) |
| Ruxolitinib, n (%) | 5 (10) | 4 (17) | 1 (4) |
| Evolution to secondary myelofibrosis, n (%) | 8 (16) | 3 (13) | 5 (20) |
| Time to leukemic transformation (range), y | 12 (1-30) | 11 (2-30) | 12 (1-30) |
| Karyotype at leukemic transformation, n (%) | n = 35 | n = 17 | n = 18 |
| Normal | 13 (37) | 6 (35) | 7 (39) |
| Abnormal not complex | 6 (17) | 4 (24) | 2 (11) |
| Complex | 9 (26) | 5 (29) | 4 (22) |
| Monosomal | 7 (20) | 2 (12) | 5 (28) |
| Post-AML treatment, n (%) | |||
| Best supportive care | 23 (47) | 13 (54) | 10 (40) |
| Low-dose cytarabine | 2 (4) | 1 (4) | 1 (4) |
| Azacytidine | 14 (29) | 6 (25) | 8 (32) |
| Intensive chemotherapy | 10 (20) | 4 (17) | 6 (24) |
| Allograft | 7 (14) | 3 (13) | 4 (16) |
| Post-AML events | |||
| Deaths, n (%) | 37 (82) | 19 (79) | 18 (79) |
| Median survival, mo | 8 | 6 | 8 |
| Patient characteristics . | Entire cohort (N = 49) . | PV (n = 24) . | ET (n = 25) . |
|---|---|---|---|
| Sex, male/female | 30/19 | 18/6 | 12/13 |
| Age at diagnosis (range), y | 63 (26-82) | 65 (42-81) | 59 (26-82) |
| Hemoglobin at diagnosis (range), g/dL | 16 (10-20.7) | 18.1 (16-20.7) | 14.4 (10-16.6) |
| Platelets at diagnosis (range), ×109/L | 624 (139-1575) | 404 (139-748) | 800 (471-1575) |
| Leukocytes at diagnosis (range), ×109/L | 9.17 (3-27.8) | 10.6 (5.1-27.8) | 8.4 (3-17.3) |
| Driver mutation, n (%) | |||
| JAK2V617F | 39 (80) | 24 (100) | 15 (60) |
| CALR | 6 (12) | — | 6 (24) |
| MPL | 2 (4) | — | 2 (8) |
| Triple negative | 2 (4) | — | 2 (8) |
| Treatment of chronic phase | |||
| Treatments, n (range) | 1 (1-5) | 1 (1-4) | 1 (1-5) |
| Hydroxycarbamide, n (%) | 39 (80) | 20 (83) | 19 (76) |
| Pipobroman, n (%) | 17 (35) | 10 (42) | 7 (28) |
| Peg IFN-α, n (%) | 6 (12) | 2 (8) | 4 (16) |
| Ruxolitinib, n (%) | 5 (10) | 4 (17) | 1 (4) |
| Evolution to secondary myelofibrosis, n (%) | 8 (16) | 3 (13) | 5 (20) |
| Time to leukemic transformation (range), y | 12 (1-30) | 11 (2-30) | 12 (1-30) |
| Karyotype at leukemic transformation, n (%) | n = 35 | n = 17 | n = 18 |
| Normal | 13 (37) | 6 (35) | 7 (39) |
| Abnormal not complex | 6 (17) | 4 (24) | 2 (11) |
| Complex | 9 (26) | 5 (29) | 4 (22) |
| Monosomal | 7 (20) | 2 (12) | 5 (28) |
| Post-AML treatment, n (%) | |||
| Best supportive care | 23 (47) | 13 (54) | 10 (40) |
| Low-dose cytarabine | 2 (4) | 1 (4) | 1 (4) |
| Azacytidine | 14 (29) | 6 (25) | 8 (32) |
| Intensive chemotherapy | 10 (20) | 4 (17) | 6 (24) |
| Allograft | 7 (14) | 3 (13) | 4 (16) |
| Post-AML events | |||
| Deaths, n (%) | 37 (82) | 19 (79) | 18 (79) |
| Median survival, mo | 8 | 6 | 8 |
Quantitative variables are summarized as median and ranges.